- Learning Objective 1: Participants will be able to identify the prognostic factors that differentiate between benign and aggressive MS
- Learning Objective 2: Participants will know the mechanisms of action, risks and benefits of different MS disease modifying agents
- Learning Objective 3: Participants will be able to decide when to choose between inducation and escalation therapy.
Tuesday, January 14, 2020 - 8:00am to 9:00am
Susan Rubin, MD
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation